financetom
Business
financetom
/
Business
/
Why did Trell Co-Founder send an angry note to investors? What we know so far
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why did Trell Co-Founder send an angry note to investors? What we know so far
Mar 25, 2022 10:49 AM

In what could be a replay of the boardroom battle at BharatPe, social commerce startup Trell Co-Founder Pulkit Agarwal shot a fiery letter to investors last week questioning the nature of a forensic audit that was conducted by EY India. In the letter, Agarwal claimed the audit was not ordered by the company or the board but by a cohort of select financial backers.

Share Market Live

NSE

A forensic team from EY India, which conducted a detailed investigation into the finances of the Bengaluru-based startup, had submitted an interim report, The Economic Times reported on March 12. The EY India team has been looking into alleged financial irregularities and related party transactions by its founders.

Also read: Ashneer Grover resigns from BharatPe, sends scathing resignation letter to board; read it here

What’s happening at Trell?

Pulkit Agrawal, Arun Lodhi, Prashant Sachan and Bimal Kartheek Rebba founded Trell in 2016 as a community-based social network, which soon became India’s fastest-growing lifestyle community-commerce platform. Trell pivoted to a lifestyle-centric short video app, before entering into video commerce model in 2021. Sachan moved out of Trell the same year to build his spiritual and devotional tech startup AppsForBharat.

The company was in talks with e-commerce giant Amazon and a clutch of investors over raising $150 million in January this year, Moneycontrol reported. Existing investors, Mirae Asset and fashion retailer H&M, were also likely to invest, the report said. Sequoia Capital India, KTB Network, Beenext, Fosun and Samsung Venture Investment are the other top institutional investors in Trell.

Also read: Sacked by BharatPe, Madhuri Jain Grover unleashes Twitter storm against company brass

However, talks were stalled on the back of an audit carried out by EY in early March, The Economic Times reported.

“There is an investigation underway on related party transactions and its scale in the company,” a source told ET. According to sources, the team was looking into an issue surrounding the monthly transacting users and revenues, the details of which will be submitted in the final report.

Also read: Bitter boardroom battles of India Inc

Pulkit’s wrath

Pulkit Agrawal refuted the allegations and sent a fiery note to the company’s angel and existing investors, saying what started as an inspection by an investor has now turned into a ‘witch hunt.’

He said the founders were not just financially invested in Trell, but emotionally involved in the company as well.

“(The founders) will not take a hit on their reputation lying down. If forced, we will do all that is within our command to protect our reputation and interest of the company and its shareholders,” the note reviewed by The Economic Times said.

Also read: Zee-Invesco boardroom battle: Bombay HC reserves order on the matter

Talks of job loss

Amid the probe, news emerged of the influencer-led social commerce startup planning to lay off 40-50 percent of its workforce.

“Trell is likely to lay off close to 300 people with immediate effect,” Entrackr reported quoting sources. The company has 700 employees, of which 500 work full time.

An employee told Moneycontrol that Trell was waiting for the board’s decision for restructuring internally. Meanwhile, the company has sent an internal communication to its employees, asking them not to panic.

Also read: Big Deal: Shareholder activism on the rise; here's what it means according to experts

(Edited by : Shoma Bhattacharjee)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cincinnati Financial Q4 Non-GAAP Operating Income Rises, Revenue Falls; Shares Gain After Hours
Cincinnati Financial Q4 Non-GAAP Operating Income Rises, Revenue Falls; Shares Gain After Hours
Feb 10, 2025
04:14 PM EST, 02/10/2025 (MT Newswires) -- Cincinnati Financial ( CINF ) reported Q4 non-GAAP operating income late Monday of $3.14 per diluted share, up from $2.28 a year earlier. Analysts polled by FactSet expected operating EPS of $1.90. Revenue in the three months ended Dec. 31 fell to $2.54 billion down from $3.36 billion a year earlier. Analysts surveyed...
Amkor Technology Q4 Earnings, Sales Decline; Q1 Outlook Issued -- Shares Drop After Hours
Amkor Technology Q4 Earnings, Sales Decline; Q1 Outlook Issued -- Shares Drop After Hours
Feb 10, 2025
04:14 PM EST, 02/10/2025 (MT Newswires) -- Amkor Technology ( AMKR ) reported Q4 earnings late Monday of $0.43 per diluted share, down from $0.48 a year earlier. Analysts surveyed by FactSet expected $0.37. Net sales for the quarter ended Dec. 31 were $1.63 billion, down from $1.75 billion a year earlier. Analysts polled by FactSet expected $1.66 billion. For...
Lattice Semiconductor Q4 Non-GAAP EPS, Revenue Decrease; Q1 Outlook Issued
Lattice Semiconductor Q4 Non-GAAP EPS, Revenue Decrease; Q1 Outlook Issued
Feb 10, 2025
04:16 PM EST, 02/10/2025 (MT Newswires) -- Lattice Semiconductor ( LSCC ) reported Q4 non-GAAP earnings Monday of $0.15 per diluted share, down from $0.45 a year earlier. Analysts polled by FactSet expected $0.19. Revenue for the quarter ended Dec. 28 was $117.4 million, down from $170.6 million a year earlier. Analysts surveyed by FactSet expected $117.1 million. The company...
Iovance Biotherapeutics Shares Fell Today: What's Going On?
Iovance Biotherapeutics Shares Fell Today: What's Going On?
Feb 10, 2025
Iovance Biotherapeutics Inc. ( IOVA ) shares closed lower on Monday as the company announced Dan Kirby as Chief Commercial Officer. What To Know: The move comes as Iovance aims to strengthen its commercial strategy amid the U.S. launch of Amtagvi and the expansion of Proleukin. Kirby brings extensive experience in commercializing cell therapy products, having previously led market access,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved